Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 5/2001

01-07-2001 | ORIGINAL ARTICLE

Comparative analysis of IFN-γ B7.1 and antisense TGF-β gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma

Authors: Rita S. Wu, James J. Kobie, David G. Besselsen, Tim C. Fong, Vivian D. Mack, Julie A. McEarchern, Emmanuel T. Akporiaye

Published in: Cancer Immunology, Immunotherapy | Issue 5/2001

Login to get access
Metadata
Title
Comparative analysis of IFN-γ B7.1 and antisense TGF-β gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma
Authors
Rita S. Wu
James J. Kobie
David G. Besselsen
Tim C. Fong
Vivian D. Mack
Julie A. McEarchern
Emmanuel T. Akporiaye
Publication date
01-07-2001
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 5/2001
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620100197

Other articles of this Issue 5/2001

Cancer Immunology, Immunotherapy 5/2001 Go to the issue

ORIGINAL ARTICLE

Th1-cytokine induction and anti-tumor effect of 55 kDa protein isolated from Aeginetia indica L., a parasitic plant

ORIGINAL ARTICLE

Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions

ORIGINAL ARTICLE

Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector

ORIGINAL ARTICLE

Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial

ORIGINAL ARTICLE

Renal carcinoma cell lines inhibit natural killer activity via the CD94 receptor molecule
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits